| Code | 2363E | ||||||||||
| MA number | 59/0286/22-S | ||||||||||
| Product Form: | cps end 56x240 mg (blis.Al//PVC/PVDC) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Sandoz Pharmaceuticals d.d., Slovenia | ||||||||||
| Therapeutic Class: | 59 - IMMUNOPRAEPARATA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | blister Al/PVC/PVDC | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 25.11.2022 |
| Validity: | 25.11.2027 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| PIL: |
PIL_Dimtruzic_120mg_240mg_cps end_11_2024.pdf
|
| SPC: |
SPC_Dimtruzic_120mg_240mg_cps end_11_2024.pdf
|
| Safety feature | Unknown |
| Data update: | 03.02.2023 |
